Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

NCT01471964 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
22
Enrollment
OTHER
Sponsor class

Stopped Phase I portion completed. Phase II will open pending amendment approval.

Conditions

Interventions

Sponsor

Fox Chase Cancer Center

Collaborators